Common cholesterol-busting pill cuts death risk of critical illness 39pc
People who are critically ill with sepsis may be more likely to survive if they are given statins, a new study suggests. Researchers wanted to explore whether the cholesterol-busting drugs may bring additional benefits for patients.
The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3% of 6,000 sepsis patients who were given statins died within 28 days.
This is compared with 23.4% of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39% reduced risk of death within a month.
READ MORE: Android users urged to update their phones 'immediately' for this reason
READ MORE: Watchdog's warning over prices at Sports Direct
The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4% of statin patients died while in the intensive care unit compared with 13.6% of those who did not receive statins. And during their overall hospital stay, some 11.5% of sepsis patients who were given statins died, compared with 19.1% of sepsis patients who did not take statins.
However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology.
Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year.
UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood.
But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings.
'Our large, matched cohort study found that treatment with statins was associated with a 39% lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.'
Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial.
'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
US-backed Gaza aid group says people 'desperately need more aid'
A privately run aid organisation brought in to distribute food rations in war-hit Gaza last month with US and Israeli backing said on Saturday that people in the Palestinian territory "desperately need more aid". The Gaza Humanitarian Foundation (GHF) began operations at the end of May when Israel eased a two-month blockade on Gaza that the United Nations said had produced famine-like conditions. The foundation's operations have been marred by chaotic scenes and neutrality concerns, while many Gazans have been left with few other options to obtain food. In a statement on Saturday, GHF interim executive director John Acree said that the organisation was "delivering aid at scale, securely and effectively... But we cannot meet the full scale of need while large parts of Gaza remain closed." He added: "The people of Gaza desperately need more aid and we are ready to partner with other humanitarian groups to expand our reach to those who need help the most." "We are working with the government of Israel to honour its commitment and open additional sites in northern Gaza." According to figures issued on Saturday by the health ministry in the Hamas-run Gaza Strip, at least 450 people have been killed and nearly 3,500 injured by Israeli fire while seeking aid since late May, many near GHF sites according to rescuers. GHF has denied responsibility for deaths near its aid points, contradicting statements from witnesses and Gaza rescue services. It has said deaths have occurred near UN food convoys. Gaza's civil defence agency said Saturday that Israeli troops had killed another eight people who were seeking food. Civil defence spokesman Mahmud Bassal told AFP that three people were killed by gunfire in the southern Gaza Strip, with another five killed in a central area known as the Netzarim corridor, where thousands of Palestinians have gathered daily in the hope of receiving rations from a GHF centre. Israeli restrictions on media in the Gaza Strip and difficulties in accessing some areas mean AFP is unable to independently verify the tolls and details provided by rescuers and authorities. UN agencies and major aid groups have refused to cooperate with GHF over concerns it was designed to cater to Israeli military objectives. On Tuesday, the UN's World Health Organization pleaded for fuel to be allowed into Gaza to keep its remaining hospitals running, warning the Palestinian territory's health system was at "breaking point". adp/ami
Bloomberg
an hour ago
- Bloomberg
Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.
Yahoo
an hour ago
- Yahoo
Sword Health Now Valued At $4 Billion, Announces Expansion Into Mental Health Services
Sword Health announced Tuesday that it had raised $40 million in a recent funding round, giving it a $4 billion valuation. Founded in 2015, the healthcare startup has focused on helping people manage chronic pain at home. Using AI tools, the platform connects users with expert clinicians who then provide patients with tools for digital physical therapy, pelvic health, and overall mobility health. However, the company says this new round of funding will largely go towards developing a mental health arm of its program called Mind. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can "Today, nearly 1 billion people worldwide live with a mental health condition. Yet care remains fragmented, reactive, and inaccessible," Sword said in the announcement. "Mind redefines mental health care delivery with a proactive, 24/7 model that integrates cutting-edge AI with licensed, Ph.D-level mental health specialists. Together, they provide seamless, contextual, and responsive support any time people need it, not just when they have an appointment." Sword CEO Virgílio Bento told CNBC, "[Mind] really a breakthrough in terms of how we address mental health, and this is only possible because we have AI." Users will be equipped with a wearable device called an M-band, which will measure their environmental and physiological signals so that experts can reach out proactively as needed. The program will also offer access to services like traditional talk therapy. Bento told CNBC that a human is "always involved" in patients care in each of its programs, and that AI is not making any clinical decisions. Trending: Maximize saving for your retirement and cut down on taxes: . For example, if a Sword patient has an anxiety attack, AI will identify it through the wearable and bring it to the attention of a clinician, who can then provide an appropriate care plan. "You have an anxiety issue today, and the way you're going to manage is to talk about it one week from now? That just doesn't work," Bento told CNBC. "Mental health should be always on, where you have a problem now, and you can have immediate help in the moment." According to Bento, Sword Mind already has a waiting list, and is being tested by some of its partners who appreciate it's "personalized approach and convenience." "We believe that it is really the future of how mental health is going to be delivered in the future, by us and by other companies," he told CNBC. "AI plays a very important role, but the use of AI — and I think this is very important — needs to be used in a very smart way." The rest of the cash raised in the funding round, which was led by General Catalyst, will go towards acquisitions, global expansion, and AI development, Sword Health says. Read Next: Here's what Americans think you need to be considered Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Sword Health Now Valued At $4 Billion, Announces Expansion Into Mental Health Services originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
